A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
- Authors
- Oh, Sung Yong; Kim, Won Seog; Kim, Jin Seok; Chae, Yee Soo; Lee, Gyeong-Won; Eom, Hyeon Seok; Ryoo, Hun Mo; Lee, Suee; Kim, Seok Jin; Yoon, Dok Hyun; Won, Jong Ho; Hong, Junshik; Park, Jinny; Lee, Sang-Min; Hong, Jung Yong; Park, Eunkyung; Kim, Hyo Jung; Yang, Deok-Hwan; Kim, Hyo-Jin; Suh, Cheolwon
- Issue Date
- Jun-2016
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Oxaliplatin; prednisone; relapse; refractory; marginal zone lymphoma
- Citation
- LEUKEMIA & LYMPHOMA, v.57, no.6, pp.1406 - 1412
- Journal Title
- LEUKEMIA & LYMPHOMA
- Volume
- 57
- Number
- 6
- Start Page
- 1406
- End Page
- 1412
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8194
- DOI
- 10.3109/10428194.2015.1099650
- ISSN
- 1042-8194
- Abstract
- Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130mg/m(2) on day 1 and prednisone 100mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range=27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate=64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI=2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8194)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.